- In January 2025, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray. This approval makes SPRAVATO the first and only monotherapy for adults with major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants
- In December 2024, Mind Medicine (MindMed) Inc. announced that the first patient had been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized version of lysergide D-tartrate (LSD) for treating generalized anxiety disorder (GAD). The Voyage study is the first of two Phase 3 trials assessing the efficacy and safety of MM120 ODT compared to a placebo, with an expected enrollment of around 200 participants in the United States. The second Phase 3 trial, the Panorama study, will be conducted in both the U.S. and Europe and is slated to begin in the first half of 2025
- In October 2024, AbbVie and Gedeon Richter Plc. announced a new agreement for the discovery, co-development, and licensing of novel targets aimed at treating neuropsychiatric conditions. This collaboration builds on their nearly two-decade-long partnership in central nervous system (CNS) projects, which has led to the global launch of products such as cariprazine (VRAYLAR / REAGILA) and the discovery of the investigational drug candidate ABBV-932, designed to treat bipolar depression and generalized anxiety disorder
- In September 2023, Pharmanovia announced the expansion of its neurology portfolio through the acquisition of 11 central nervous system (CNS) brands from Sanofi, a global healthcare company. These brands cover four key therapeutic areas with ongoing unmet needs in CNS disorders: psycholeptic, anxiolytic, anti-epileptic, and anti-psychotic
- In March 2023, Pharmanovia announced the expansion of its exclusive license and supply agreement with Aquestive Therapeutics, Inc. for its patented diazepam buccal film formulation. The expanded agreement now covers the rest of the world, excluding the U.S., Canada, and China. Diazepam, a member of the benzodiazepine class of medicines, is used to treat conditions such as anxiety, muscle spasms, and seizures
